| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:OCS) with a Buy and maintains $51 price target.
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $3...
Needham analyst Serge Belanger reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $36 price target.
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50)...
Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotectiv...